Premium
Pachyonychia congenita with corneal dystrophy
Author(s) -
Guo Hong,
Liu Dan,
Wu Jun,
Liao Qiong,
Bai Yun
Publication year - 2013
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/1346-8138.12183
Subject(s) - china , medical genetics , medical school , medicine , corneal dystrophy , family medicine , medical science , ophthalmology , library science , medical education , history , genetics , biology , cornea , archaeology , computer science , gene
label, phase III study. Lancet Oncol 2009; 10: 223–232. 2 Santini V, Fenaux P, Mufti GJ et al. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine. Eur J Haematol 2010; 85: 130–138. 3 Fandy TE, Carraway H, Gore SD. DNA demethylating agents and histone deacetylase inhibitors in hematologic malignancies. Cancer J 2007; 13: 40–48. 4 Almeida AM, Pierdomenico F. Generalized skin reactions in patients with MDS and CMML treated with azacitidine: effective management with concomitant prednisolone. Leuk Res 2012; 36: e211–e213. 5 Tintle S, Patel V, Ruskin A et al. Azacitidine: a new medication associated with Sweet syndrome. J Am Acad Dermatol 2011; 64: e77– e79.